EATG » Hepatitis

Hepatitis

Switching to TAF for hepatitis B improves kidney function and bone loss

People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss,…

Nivolumab increases survival for people with advanced liver cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers…

Solving the hepatitis C epidemic among people with substance abuse disorders

Annals of Internal Medicine editorial by UB professor describes innovations in HCV treatment at methadone clinics and corrections facilities BUFFALO, N.Y., April 24, 2017 — One of the most dramatic medical…

Blood donor screening for hepatitis E reveals incidence is higher than previously reported

Results from a hepatitis E virus (HEV) RNA screening centre in Germany suggest need for routine screening to prevent viral transmission to the immunocompromised April 21, 2017, Amsterdam, The Netherlands:…

Adherence, SVR unaffected by drug use in patients with HCV

AMSTERDAM — Adherence to treatment and subsequent sustained virologic response were unaffected by drug use in a study of patients enrolled in an opioid agonist treatment program, according to a…

Glecaprevir/pibrentasvir effective in liver, kidney transplant patients with HCV

AMSTERDAM — Nearly 100% of a cohort of non-cirrhotic patients with HCV who had undergone liver transplantation responded to treatment with glecaprevir/pibrentasvir, according to data presented at the International Liver…

DAAs may impact inflammatory markers in cirrhosis, HCC surveillance

AMSTERDAM — Curing patients with cirrhosis of hepatitis C virus could alter the inflammatory milieu and have an impact on the way CD8+ T-cells surveil potential carcinoma, according to data…

One-third of UK adolescents with HCV developed serious liver disease

AMSTERDAM — Approximately one-third of children under 18 years in the United Kingdom with hepatitis C developed serious long-term liver disease, according to data presented at the International Liver Congress.…

Early treatment of HCV reduces extrahepatic morbidity, mortality

AMSTERDAM — Dealing with hepatitis C virus as a systemic disease, and not just a complication of the liver, may aid clinicians in reducing extrahepatic manifestations of the infection, according…

Expert: Three HCV drugs may not be better than two

AMSTERDAM — The benefits of both double and triple direct-acting antiviral therapy combinations depend on myriad patient and disease factors, according to findings presented at the International Liver Congress. Jean-Michel…